Welcome to our dedicated page for Cardio Diagnostics Holdings news (Ticker: CDIO), a resource for investors and traders seeking the latest updates and insights on Cardio Diagnostics Holdings stock.
Cardio Diagnostics Holdings, Inc. reports developments in precision cardiovascular medicine, including AI-driven genetic and epigenetic blood tests for coronary heart disease. The company’s commercial products include Epi+Gen CHD, which assesses three-year risk for a coronary heart disease event, and PrecisionCHD, which aids in CHD diagnosis and management.
Recurring updates include clinical data for cardiovascular disease detection, CMS reimbursement and MolDX payment-rate activity, provider-network expansion, community health partnerships, and commercialization efforts for physician-ordered testing. Company communications also describe its Integrated Genetic-Epigenetic Engine and broader cardiovascular disease prevention, detection, and management strategy.
Cardio Diagnostics Holdings (NASDAQ: CDIO) is sponsoring Becker’s Hospital Review 11th Annual Meeting from November 7-10, 2022, in Chicago. CEO Meesha Dogan will present on epigenetics in heart disease at booth #120. The conference attracts over 1,000 healthcare leaders to address critical issues in hospital management. Cardio’s mission focuses on advancing cardiovascular disease detection and treatment through its proprietary Integrated Genetic-Epigenetic Engine, developed at the University of Iowa. This technology aims to enhance personalized cardiovascular care and risk stratification.